Literature DB >> 23913475

Inhibiting glycogen synthesis prevents Lafora disease in a mouse model.

Bartholomew A Pederson1, Julie Turnbull, Jonathan R Epp, Staci A Weaver, Xiaochu Zhao, Nela Pencea, Peter J Roach, Paul W Frankland, Cameron A Ackerley, Berge A Minassian.   

Abstract

Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.
© 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913475      PMCID: PMC3823666          DOI: 10.1002/ana.23899

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

1.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

2.  Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise.

Authors:  Bartholomew A Pederson; Carlie R Cope; Jill M Schroeder; Micah W Smith; José M Irimia; Beth L Thurberg; Anna A DePaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2005-02-11       Impact factor: 5.157

3.  Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis.

Authors:  Jaiprakash Sharma; Sudheendra N R Rao; Susarla Krishna Shankar; Parthasarathy Satishchandra; Nihar Ranjan Jana
Journal:  Neurobiol Dis       Date:  2011-06-25       Impact factor: 5.996

Review 4.  Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia.

Authors:  David A Weinstein; Catherine E Correia; Andrew C Saunders; Joseph I Wolfsdorf
Journal:  Mol Genet Metab       Date:  2005-12-06       Impact factor: 4.797

5.  Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin.

Authors:  Sudheendra N R Rao; Ranjan Maity; Jaiprakash Sharma; Parthanarayan Dey; Susarla Krishna Shankar; Parthasarathy Satishchandra; Nihar Ranjan Jana
Journal:  Hum Mol Genet       Date:  2010-09-21       Impact factor: 6.150

6.  Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.

Authors:  Karen M Ashe; Kristin M Taylor; Qiuming Chu; Elizabeth Meyers; Allen Ellis; Varvara Jingozyan; Katherine Klinger; Patrick F Finn; Christopher G F Cooper; Wei-Lien Chuang; John Marshall; John M McPherson; Robert J Mattaliano; Seng H Cheng; Ronald K Scheule; Rodney J Moreland
Journal:  Mol Genet Metab       Date:  2010-05-05       Impact factor: 4.797

7.  Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.

Authors:  Vincent S Tagliabracci; Jean Marie Girard; Dyann Segvich; Catalina Meyer; Julie Turnbull; Xiaochu Zhao; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

8.  Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0.

Authors:  Gittan Kollberg; Már Tulinius; Thomas Gilljam; Ingegerd Ostman-Smith; Gun Forsander; Peter Jotorp; Anders Oldfors; Elisabeth Holme
Journal:  N Engl J Med       Date:  2007-10-11       Impact factor: 91.245

9.  Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.

Authors:  Rajat Puri; Toshimitsu Suzuki; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

10.  PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease.

Authors:  Julie Turnbull; Anna A DePaoli-Roach; Xiaochu Zhao; Miguel A Cortez; Nela Pencea; Erica Tiberia; Mark Piliguian; Peter J Roach; Peixiang Wang; Cameron A Ackerley; Berge A Minassian
Journal:  PLoS Genet       Date:  2011-04-28       Impact factor: 5.917

View more
  43 in total

Review 1.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

2.  Glycogen: the missing link in neuronal autophagy?

Authors:  Akanksha Onkar; Deepashree Sheshadri; Subramaniam Ganesh
Journal:  Autophagy       Date:  2020-08-02       Impact factor: 16.016

3.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

Review 4.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

5.  Discovery and Development of Small-Molecule Inhibitors of Glycogen Synthase.

Authors:  Buyun Tang; Mykhaylo S Frasinyuk; Vimbai M Chikwana; Krishna K Mahalingan; Cynthia A Morgan; Dyann M Segvich; Svitlana P Bondarenko; Galyna P Mrug; Przemyslaw Wyrebek; David S Watt; Anna A DePaoli-Roach; Peter J Roach; Thomas D Hurley
Journal:  J Med Chem       Date:  2020-03-23       Impact factor: 7.446

6.  Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.

Authors:  Arnaud Berthier; Miguel Payá; Ana M García-Cabrero; Maria Inmaculada Ballester; Miguel Heredia; José M Serratosa; Marina P Sánchez; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2015-01-28       Impact factor: 5.590

7.  A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease.

Authors:  Leonardo J Solmesky; Netaly Khazanov; Hanoch Senderowitz; Peixiang Wang; Berge A Minassian; Igor M Ferreira; Wyatt W Yue; Alexander Lossos; Miguel Weil; Or Kakhlon
Journal:  Biochem J       Date:  2017-09-28       Impact factor: 3.857

8.  A novel mouse model that recapitulates adult-onset glycogenosis type 4.

Authors:  H Orhan Akman; Valentina Emmanuele; Yasemin Gülcan Kurt; Bülent Kurt; Tatiana Sheiko; Salvatore DiMauro; William J Craigen
Journal:  Hum Mol Genet       Date:  2015-09-18       Impact factor: 6.150

Review 9.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

10.  Efficacy and tolerability of perampanel in ten patients with Lafora disease.

Authors:  Danielle Goldsmith; Berge A Minassian
Journal:  Epilepsy Behav       Date:  2016-07-25       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.